How Can Advanced Prostate Cancer Disparities Be Reduced? from Patient Empowerment Network on Vimeo.
What are some ways that advanced prostate cancer disparities can be reduced? Expert Dr. Isaac Powell from Karmanos Cancer Institute discusses early detection, recommended screening ages for African Americans versus European Americans, and how some government agencies can aid in reducing disparities.
See More from [ACT]IVATED Prostate Cancer
Related Resources:
Transcript:
Lisa Hatfield:
So, Dr. Powell, in your work, have you come across any innovative approaches or interventions that have shown promise in reducing racial disparities and improving outcomes for patients with advanced prostate cancer?
Dr. Isaac Powell:
Yes. Number one, educating the community about prostate cancer. Early detection is extremely important. I tell them that they should get their PSAs and digital rectal exams. I also tell them again, about obesity and exercise, how important it is to do that because it may prevent prostate cancer. And in terms of advanced disease, to just try to do the best they can and prolong in the survival by participating in clinical trials. And so I do quite a bit of educating in the African American community. In fact, in the ‘90s, we went to 51 churches, African American churches to talk about the prostate cancer and we also did testing. And what we learned in the ‘90s that mistrust factor was a major factor that prevented men from going in to be tested.
We also learned that men really don’t take care of their bodies as they should, and women have played a major role in the healthcare of men. So we start educating women about prostate cancer and encouraging their husbands to come in for examination, and very frequently, the wives have to bring their husbands in for testing or insist that they do that. I have this statement, I have a slide that says, men, they better care of their cars than they do of their bodies. And, in fact, they deny that they have any symptoms, and when they do, they don’t do anything about it until it’s too late.
Lisa Hatfield:
I have one follow-up question to that too, so you mentioned screenings, and I looked up prior to talking with you just to see what the general guidelines are for screenings for men, for prostate cancer, and it seems like they run the gamut. Do you have recommendations, or do you think the recommendations will change guidelines for screening and given your data and your research, is there a difference in screenings between European Americans versus African Americans?
Dr. Isaac Powell:
Yes. Because of what I’ve been talking about the cancer grows faster, and the significant cancers, the ones that are growing faster and become metastasized began in the 40s in African Americans, and so for European Americans has been recommended testing at age 50. I recommend age 40, American Cancer Society recommends age 45. Now, I believe at age 40, and I tell my patients that’s when they should start, African Americans that is, start testing for prostate cancer, specifically the PSA and digital rectal exam, and particularly if they have a family history. Now, the family history, if they only have one or two members is not much different than the aggressiveness among African Americans or European Americans.
If they have five or six members, not just a prostate cancer, but breast cancers as well, that means that they have a strong family history for having prostate cancer. If they have breast cancer, ovarian cancer in their family, or colon cancer, lung cancer, all those cancers are responsible for having a cancer and any specific cancer, if you have prostate cancer, breast cancer, you’re at risk for having colon cancer, for example. So that’s more recently talked about, multiple cancers in the family are even more important than having just prostate cancer in your family.
Lisa Hatfield:
Dr. Powell, given your expertise, what policy changes or healthcare system reforms do you believe are necessary to tackle the racial disparities in advanced prostate cancer care on a broader scale?
Dr. Isaac Powell:
Yes, policies are made by the government essentially. And so you have to encourage CDC, Centers Disease Control, US Preventive Services, which has done a disservice and prostate cancer. In fact, in 2012 they had that PSA did not show any evidence of preventing death from prostate cancer. They rescinded that 2017 recognizing that their recommendation 2012 was incorrect, and so US Preventive Services and the CDC, as well as the National Institute of Health NIH, have to come together and say, this disease is not only prostate but breast cancer, triple-negative breast cancer, colon cancer, lung cancer, all of these are more aggressive among African Americans, and we have to make a statement that screening has to be done earlier, education has to be emphasized.
And, in fact, COVID testing, it was almost mandatory on the circumstances that that happened. We used to demand that syphilis tests be tested if you got married. The government can also make it mandatory to be tested if your age, 45, American 50 for prostate cancer and maybe other cancers as well. So the government has to play a major role in establishing policies for testing, and I think that that would be very helpful in eliminating the disparity.
Lisa Hatifield:
And then from the patient perspective, it sounds like, and just trying to clarify this to when you talk about screenings for a patient to get screened to the appropriate time, that includes both the PSA test and the digital rectal exam, is that correct?
Dr. Isaac Powell:
Absolutely.
Share Your Feedback
How Can Extensive Stage Small Cell Lung Cancer Symptoms Be Managed?
/in Lung Cancer, SCLC Activated, SCLC Activated Expert, SCLC Newly Diagnosed, SCLC Programs, SCLC Treatment and Clinical Trials, SCLC Video ND, SCLC Video TC, SCLC Video WN, SCLC Video WPS, SCLC What's Next, SCLC Whole Patient Support, Small Cell Lung Cancer, Uncategorized /by Kara RayburnHow Can Extensive Stage Small Cell Lung Cancer Symptoms Be Managed? from Patient Empowerment Network on Vimeo.
When extensive stage small cell lung cancer patients experience symptoms, how can they be managed? Expert Beth Sandy from Abramson Cancer Center discusses collaborative symptom management for ES-SCLC patients for common symptoms including respiratory issues, appetite and digestion, and neurologic symptoms.
See More from [ACT]IVATED Small Cell Lung Cancer (SCLC)
Related Resources:
Extensive Stage Small Cell Lung Cancer | Empowering Symptom Management
Small Cell Lung Cancer Care | Optimizing Team Communication
Transcript:
Lisa Hatfield:
Beth, how do you approach collaborative symptom management for newly diagnosed patients with extensive stage small cell lung cancer?
Beth Sandy:
So when you’re newly diagnosed, it really depends. A lot of our patients will end up having symptoms such as shortness of breath or a cough or even coughing up of blood just because the natural biology of small cell lung cancer tends to be a very centralized cancer, the airways. So symptoms typically are respiratory, and we have a lot of really good treatments to help with things like shortness of breath and cough. To be honest with you, this type of lung cancer is so responsive to chemotherapy that sometimes the chemotherapy alone will help your symptoms because it responds so quickly.
If that’s not the case, we can do radiation also to help minimize the cancer where it may be causing shortness of breath, or certainly if you’re coughing up blood, a lot of times we’re going to go in and do something like radiation. There are other things that we can prescribe such as inhalers or medications that are prescriptions that can help with cough like certain syrups and other pills that can help reduce cough. Those typically are often the main respiratory symptoms. Other things that we may find are things like weight loss and decreased appetite. That can be harder, I will say.
There used to be medications that we used for appetite stimulation. The problem with some of those medications is they were increasing the risk of blood clot, which is already a risk when you have lung cancer, so we don’t have to use them as often. But there are some medications that we can work with, and we work with oncology nutrition a lot as well to help patients, especially when weight loss is an issue. There’s a whole other set of side effects the patient’s going to have once they start treatment, but they usually don’t typically present with things like nausea or vomiting, or constipation or diarrhea. Those things can be side effects of treatment.
Another thing that can be common in extensive stage small cell lung cancer is metastasis to the brain. So sometimes patients will have headaches or neurologic changes, but the good thing is that’s very responsive to steroids and radiation, so the sooner we get people on treatment, really those symptoms tend to improve very quickly. The activation tip for this really would be to make sure you let the nurses and doctors know exactly what sometimes you’re experiencing, because we really do have a lot of good supportive care medications, and truthfully the treatment for the cancer should really help improve your symptoms pretty quickly with this disease.
Share Your Feedback:
Create your own user feedback survey
Small Cell Lung Cancer Clinical Trials and DeLLphi Study Update
/in Lung Cancer, SCLC Activated, SCLC Activated Expert, SCLC Newly Diagnosed, SCLC Programs, SCLC Treatment and Clinical Trials, SCLC Video ND, SCLC Video TC, SCLC Video WN, SCLC Video WPS, SCLC What's Next, SCLC Whole Patient Support, Small Cell Lung Cancer, Uncategorized /by Kara RayburnSmall Cell Lung Cancer Clinical Trials and DeLLphi Study Update from Patient Empowerment Network on Vimeo.
What value might small cell lung cancer (SCLC) clinical trial participation and the DeLLphi study offer patients? Expert Dr. Vinicius Ernani from the Mayo Clinic explains the significance of clinical trial participation and what is being studied in the DeLLphi trial for SCLC care.
[ACT]IVATION TIP
See More from [ACT]IVATED Small Cell Lung Cancer (SCLC)
Related Resources:
Understanding Small Cell Lung Cancer Research News and Future Treatments
Starting Time-Sensitive Small Cell Lung Cancer Treatment
Advice for Small Cell Lung Cancer Patients Considering Clinical Trials
Transcript:
Lisa Hatfield:
Dr. Ernani, can you speak to the importance of expression of DLL3, what it is and what it means for small cell lung cancer research, and why is clinical trial participation so important in small cell lung cancer? And what advice do you have for patients who are considering a clinical trial?
Dr. Vinicius Ernani:
Yeah, so DLL3 is a protein expressed on the cancer cell of the majority of those patients with small cell lung cancer. And that’s where, exactly where tarlatamab, which is, it’s the BiTE, the T-cell engager that I mentioned before, that’s one of the targets. So the tarlatamab, it binds to the DLL3 on the surface of the cancer cell, and also bind to the CD3 at the T cell, right?
So that activation, the tarlatamab does that bridge and that activation enhances or activates the T cells to go there and fight the cancer. What we’ve seen in DeLLphi study with the tarlatamab is that the responses are irrespective of the DLL3 expression. But that being said, again, is the target of tarlatamab. And so it, again, it binds to the DLL3 the cancer cell, and it binds to the CD3 on the T cell.
And that activation enhances the T cell to fight against the cancer. Why is clinical trial participation so important in small cell? Well, I think I encourage all my patients to participate in clinical trials because some of the treatments that you can only get in clinical trials today, they might become the standard of care tomorrow.
Let’s say patients on immunotherapy five years ago, there are still some patients that are on trial, they’re still getting immunotherapy. And now, basically every disease you can treat the patients with immunotherapy. So you never know. The trial that you are enrolled in today might be the new standard of care tomorrow, and you might be having this chance to get it very early in the course of your disease.
So my activation tip for this question is, always ask your team about clinical trials. And again, I recommend patients, if it’s a reasonable clinical trial, I will always recommend my patients to be enrolled in it.
Share Your Feedback:
Create your own user feedback survey
Understanding Small Cell Lung Cancer Research News and Future Treatments
/in Lung Cancer, SCLC Activated, SCLC Activated Expert, SCLC Newly Diagnosed, SCLC Programs, SCLC Treatment and Clinical Trials, SCLC Video ND, SCLC Video TC, SCLC Video WN, SCLC Video WPS, SCLC What's Next, SCLC Whole Patient Support, Small Cell Lung Cancer, Uncategorized /by Kara RayburnUnderstanding Small Cell Lung Cancer Research News and Future Treatments from Patient Empowerment Network on Vimeo.
What do small cell lung cancer (SCLC) treatment and the future of treatment look like? Expert Dr. Vinicius Ernani from the Mayo Clinic discusses SCLC treatment progress and small cell lung cancer clinical trials including the DeLLphi trial.
[ACT]IVATION TIP
See More from [ACT]IVATED Small Cell Lung Cancer (SCLC)
Related Resources:
Starting Time-Sensitive Small Cell Lung Cancer Treatment
Advice for Small Cell Lung Cancer Patients Considering Clinical Trials
Transcript:
Lisa Hatfield:
And, Dr. Ernani, can you please explain research advancements in immuno-oncology and what this means for extensive-stage small cell lung cancer patients? And how do you envision the treatment landscape evolving over the next five to 10 years?
Dr. Vinicius Ernani:
Yes. So over the last 30 years, we’ve had multiple Phase II, Phase III trials and, unfortunately, we were not able to move the needle in small cell lung cancer. However, over the last few years with the advancement of immunotherapy and incorporating immunotherapy to the standard carboplatin (Paraplatin) and etoposide (Toposar), we were able to finally make some progress in small cell lung cancer.
So now we know that the standard of care is to give chemotherapy plus immunotherapy, and we have at least three to four randomized Phase III trials showing the benefit of adding immunotherapy to chemotherapy. And I think this is a very exciting time for small cell. We are seeing at least over the last couple of meetings, over the last year, I’ve been seeing at least two promising drugs.
One is tarlatamab that was the Phase II studies called the DeLLphi trial, was recently presented at ESMO. And there’s also an antibody drug conjugate that has also been very promising in small cell. So we’ll see how these studies are going to play out, especially the antibody drug conjugate, that’s still a Phase I study. So it’s a little bit early, but encouraging response rates. And the tarlatamab, which is a BiTE, and what I mean by BiTE, is a bi T-cell specific engager. I think it’s probably going to be soon approved by the FDA, and I think it’s going to change the standard of care in small cell again.
Lisa Hatfield:
Dr. Ernani, with regard to the DeLLphi trial, can you explain who that is for and more specifically maybe what the hope is for patients and their families?
Dr. Vinicius Ernani:
Yeah. So the DeLLphi trial was a Phase II study. So usually we have three types of study, right? First, we have the Phase I study. Phase I studies are usually looking at how safe is a drug, but we are not looking too much of how active the drug is. We’re just making sure that the drug is safe to give to the patients. A Phase II study is a little bit bigger than a Phase I, and we are looking still at safety, if the treatment is safe, but we are trying to look a little bit more careful and how active this drug is.
In Phase III, those are usually big studies that randomizes 200, 300, 400 patients to the standard of care compared to the new drug. And that’s usually where we get the FDA approvals. So the DeLLphi-301 trial was a Phase II study that enrolled patients with heavily pretreated small cell lung cancer, extensive stage small cell lung cancer, to receive tarlatamab.
And they had two doses. It was 10 milligrams and 100 milligrams. And it seems that the 10 milligram cohort, that actually the responses were even better than the 100 milligrams. So we saw the presentation at ESMO, it was actually published in one of the most respected…probably the most respected journal of medicine, the New England Journal of Medicine, and there was a response rate of 40 percent. So if we could give tarlatamab for patients that fail at least two lines of treatment, the chances of them responding to tarlatamab is about 40 percent.
And more importantly, I think that the duration of response was greater than six months. So what I mean by that, more than 50 percent of the patients that received this drug, they controlled the cancer for at least six months. So I think that’s a very positive about this drug.
Lisa Hatfield:
Great, thank you. And then one follow-up question I have about that. So if a patient were to come to you or go to their local oncologist and say, I’m really interested, I heard about this DeLLphi trial or any clinical trial, what is the advice you would give to that patient on how to access that clinical trial?
Dr. Vinicius Ernani:
Well, unfortunately, we don’t have at our institution, what I usually help my patients, I go to clinicaltrials.gov and I type their cancer, and I go over with them on where the trials are open, and we try to find a facility or a cancer center that is close to where they live. So that’s what I usually do when I’m trying to find a clinical trial that I don’t have available in my site.
My activation tip for this question is, again, I think stay tuned. This tarlatamab might become, down the road, a new standard of care for our patients.
Share Your Feedback:
Create your own user feedback survey
Starting Time-Sensitive Small Cell Lung Cancer Treatment
/in Lung Cancer, SCLC Activated, SCLC Activated Expert, SCLC Newly Diagnosed, SCLC Programs, SCLC Treatment and Clinical Trials, SCLC Video ND, SCLC Video TC, SCLC Video WN, SCLC Video WPS, SCLC What's Next, SCLC Whole Patient Support, Small Cell Lung Cancer, Uncategorized /by Kara RayburnStarting Time-Sensitive Small Cell Lung Cancer Treatment from Patient Empowerment Network on Vimeo.
Some small cell lung cancer (SCLC) treatment calls for time-sensitive treatment. Expert Dr. Vinicius Ernani from the Mayo Clinic shares how he works with patients who will most likely have optimal results with prompt treatment and advice for patients considering rapid treatment.
[ACT]IVATION TIP
See More from [ACT]IVATED Small Cell Lung Cancer (SCLC)
Related Resources:
Understanding Small Cell Lung Cancer Research News and Future Treatments
Key Resources for Small Cell Lung Cancer Patients and Families
Transcript:
Lisa Hatfield:
Dr. Ernani, for some small cell lung cancer patients, understanding treatment options is crucial and sometimes requires swift decisions. How do you work with your patients and families to make treatment decisions that might have to be made rather rapidly?
Dr. Vinicius Ernani:
Well, small cell, as we know, it’s an aggressive type of cancer, it divides very quickly. And because of that the patients usually, they tend to be symptomatic, so they have a lot of symptoms at the time that we see them. And if this disease, if we left untreated and the patient has extensive stage, so the disease has spread, the prognosis can be poor.
That being said, because small cell divides very quickly, chemotherapy combined with immunotherapy can help these patients fairly quickly. We can see patients in a matter of two to three weeks, they report that their shortness of breath is much better, they’re feeling better, they’re more energetic, they can do more things at home.
So we can see a rapid positive response to treatment very quickly. So when I explain this to my patients, most of the patients, they have no hesitation to say, yeah, I want to proceed with chemotherapy. And I tell them chemotherapy will help you feel better and also help you survive longer. And we are very fortunate that sometimes the patients are able to live years, they’re able to meet some live, let’s say, like a wedding of a grandkid or important events in their life. So I always recommend them to at least give it a shot.
My activation tip for this question is at least give the treatment a try. I think that you’re going to be positively surprised that you’re going to feel better within a few weeks.
Share Your Feedback:
Create your own user feedback survey
[ACT]IVATED SCLC Resource Guide en Español
/in Lung Cancer, SCLC Activated, SCLC Activated Resources, SCLC Newly Diagnosed, SCLC Programs, SCLC Resource ND, SCLC Resource TC, SCLC Treatment and Clinical Trials, Small Cell Lung Cancer /by Kara RayburnDownload Resource Guide
Spanish_ACT_IVATED_SCLC_Resource_Guide_
Download Resource Guide
See More from [ACT]IVATED SCLC
[ACT]IVATED SCLC Resource Guide
/in Lung Cancer, SCLC Activated, SCLC Activated Resources, SCLC Newly Diagnosed, SCLC Programs, SCLC Resource ND, SCLC Resource TC, SCLC Treatment and Clinical Trials, Small Cell Lung Cancer /by Kara RayburnDownload Resource Guide
__ACT_IVATED_SCLC_Resource_Guide_
Download Resource Guide
See More from [ACT]IVATED SCLC
[ACT]IVATED SCLC Shared Decision Making Checklist
/in Lung Cancer, SCLC Activated, SCLC Activated Toolkit, SCLC Newly Diagnosed, SCLC Programs, SCLC Resource ND, SCLC Resource TC, SCLC Treatment and Clinical Trials, Small Cell Lung Cancer /by Kara RayburnDownload Resource Guide
SDM_Health_Literacy_and_Equity_Tools_Checklist
Download Resource Guide
See More from [ACT]IVATED SCLC
Beneficios del empoderamiento a lo largo del proceso del cáncer Guía de recursos
/in Adrenal Cancer, Adrenal Cancer Resource TC, Adrenal Cancer Treatment & Clinical Trials, Appendix Cancer, Appendix Cancer Resources TC, Appendix Cancer Treatment & Clinical Trials, Bone Cancer, Bone Cancer Resource TC, Bone Cancer Treatment & Clinical Trials, Brain Cancer, Brain Cancer Resource TC, Brain Cancer Treatment & Clinical Trials, EH HCP Resources, Empowered Health, Eye Cancer, Eye Cancer Resource TC, Eye Cancer Treatment & Clinical Trials, General Health Info, General Newly Diagnosed, General Resource ND, General Resource TC, General Treatment and Clinical Trials /by Kara RayburnDownload Resource Guide
985474-Clinician_Handout_Spanish
Download Resource Guide
See More from Empowered Health
Benefits of Empowerment Across the Cancer Continuum Resource Guide
/in Adrenal Cancer, Adrenal Cancer Resource TC, Adrenal Cancer Treatment & Clinical Trials, Appendix Cancer, Appendix Cancer Resources TC, Appendix Cancer Treatment & Clinical Trials, Bone Cancer, Bone Cancer Resource TC, Bone Cancer Treatment & Clinical Trials, Brain Cancer, Brain Cancer Resource TC, Brain Cancer Treatment & Clinical Trials, EH HCP Resources, Empowered Health, Eye Cancer, Eye Cancer Resource TC, Eye Cancer Treatment & Clinical Trials, General Health Info, General Newly Diagnosed, General Resource ND, General Resource TC, General Treatment and Clinical Trials /by Kara RayburnDownload Resource Guide
985474-Clinician_Handout_English
Download Resource Guide
See More from Empowered Health
¿De qué manera puede mejorar su salud el empoderamiento y la toma de decisiones compartida? Guía de recursos
/in Adrenal Cancer, Adrenal Cancer Resource TC, Adrenal Cancer Treatment & Clinical Trials, Appendix Cancer, Appendix Cancer Resources TC, Appendix Cancer Treatment & Clinical Trials, Bone Cancer, Bone Cancer Resource TC, Bone Cancer Treatment & Clinical Trials, Brain Cancer, Brain Cancer Resource TC, Brain Cancer Treatment & Clinical Trials, EH Patient Resources, Empowered Health, Eye Cancer, Eye Cancer Resource TC, Eye Cancer Treatment & Clinical Trials, General Health Info, General Newly Diagnosed, General Resource ND, General Resource TC, General Treatment and Clinical Trials /by Kara RayburnDownload Resource Guide
985474-Patient_Handout_Spanish
Download Resource Guide
See More from Empowered Health
How Can Empowerment and Shared Decision Making Improve Your Health? Resource Guide
/in Adrenal Cancer, Adrenal Cancer Resource TC, Adrenal Cancer Treatment & Clinical Trials, Appendix Cancer, Appendix Cancer Resources TC, Appendix Cancer Treatment & Clinical Trials, Bone Cancer, Bone Cancer Resource TC, Bone Cancer Treatment & Clinical Trials, Brain Cancer, Brain Cancer Resource TC, Brain Cancer Treatment & Clinical Trials, EH Patient Resources, Empowered Health, Eye Cancer, Eye Cancer Resource TC, Eye Cancer Treatment & Clinical Trials, General Health Info, General Newly Diagnosed, General Resource ND, General Resource TC, General Treatment and Clinical Trials /by Kara RayburnDownload Resource Guide
985474-Patient_Handout_English
Download Resource Guide
See More from Empowered Health
Dr. Isaac Powell: Why Is It Important for You to Empower Patients?
/in EPEP, EPEP Videos /by Kara RayburnDr. Isaac Powell: Why Is It Important for You to Empower Patients? from Patient Empowerment Network on Vimeo.
What are some ways that cancer patients can be empowered by healthcare providers? Expert Dr. Isaac Powell from Karmanos Cancer Institute shares his perspective on ways patients can take charge of their health and situations that may be outside their control.
See More from Empowering Providers to Empower Patients (EPEP)
Related Resources:
Dr. Ronald Chen: Why Is It Important for You to Empower Patients?
Dr. Yaw Nyame: Why Is It Important for You to Empower Patients?
Transcript:
Dr. Isaac Powell:
I tell my patients that they have to take charge of their health. They have to talk to the doctor. You have to ask the doctor challenging questions. Then you have to do things that are going to help you as well. You have to be responsible for your own health, such as losing weight if necessary, such as exercising if necessary.
There are things that can cause things that you can’t control, like the pollution of the air and the water. But even in those situations, you need to challenge that and say, we need to do something about this polluted area where I’m living. And so those are the kinds of things that I discuss with my patients. Take charge of your health in every aspect.
Dr. Ronald Chen: Why Is It Important for You to Empower Patients?
/in EPEP, EPEP Videos /by Kara RayburnDr. Ronald Chen: Why Is It Important for You to Empower Patients? from Patient Empowerment Network on Vimeo.
Empowering patients and care partners is key to helping them to make informed care decisions. How can experts provide the right information about various options based on what matters most to the patient? Prostate cancer expert Dr. Ronald Chen with the University of Kansas Medical Center shares his approach to empowering patients so they can make the individual decision for them and their family.
See More from Empowering Providers to Empower Patients (EPEP)
Related Resources:
Dr. Silvina Pugliese: Why Is It Important for You to Empower Patients?
Dr. Yaw Nyame: Why Is It Important for You to Empower Patients?
Transcript:
Dr. Ronald Chen:
I empower my patients by giving them the necessary information, so that patients and their caregivers are empowered to make the best decision for them. I think for every cancer patient, there’s always a balance that’s struck between how aggressive the treatment should be, and also how important quality of life is to them. And every patient may make a different decision among the different options that are available.
So as a physician, giving patients the right information about the different options and about the implications in terms of side effects and quality of life and survival is so important, so that each patient is empowered to make the individual decision for them and their family.
Are There Worldwide Links to Aggressive Prostate Cancer?
/in PC Activated, PC Activated Expert Interviews, PC Videos WPS, PC Whole Patient Support, Prostate Cancer /by Kara RayburnAre There Worldwide Links to Aggressive Prostate Cancer? from Patient Empowerment Network on Vimeo.
Does aggressive prostate cancer occur more often in specific population groups? Expert Dr. Isaac Powell from Karmanos Cancer Institute discusses some regions with high prostate cancer incidence outside the U.S., the impact of inflammatory cytokines, and how screening recommendations may change.
See More from [ACT]IVATED Prostate Cancer
Related Resources:
How Can Advanced Prostate Cancer Care Barriers Be Overcome?
How Can Prostate Cancer Disparity Gaps Be Overcome?
How Can Advanced Prostate Cancer Disparities Be Reduced?
Transcript:
Lisa Hatfield:
So, Dr. Powell, worldwide are there factors that drive aggressive prostate cancer?
Dr. Isaac Powell:
Yes, let me address that. In 2015 it was reported that in Ghana, the incidence of prostate cancer was higher than in the United States. It’s also been found in the Caribbean, Jamaica specifically in Haiti, that the incidence in prostate cancer is greater than among African Americans in this country. So that takes us to the question of what is it about Africa that’s responsible for this aggressive cancer. And so I’ve been looking into that issue and finding that it’s not all Sub-Saharan Africa, it’s the West Africa. It’s consistent with the slave trade and what is it about West Africa and also Central Africa that is causing this. And I also found that in East Africa, the incidences of prostate cancer as well as breast cancer is less than West Africa. So what now we’re talking about the environment. What is it about the environment of West Africa versus East Africa. And the environment is in West Africa considered a rainforest and in East Africa is considered a different environment.
The diseases are different. In West Africa, you have such disease as a malaria and yellow fever, acute inflammatory diseases, West Africa, I mean East Africa, you don’t have that you have other things. So it’s the environment of West Africa, the rainforest specifically that causes those particular diseases. Now the genetics is, in those poor inflammatory cytokines that we’ve discussed that causes prostate cancer and, in fact, other benign diseases to be more progressive, protect against these acute infections. So this is…the immune system is very complex. In some cases it protects, in some cases it drives the cancers. This is what is…therefore, cancer is what is called an autoimmune disease. And so what the protection does, it selects the population in West Africa. The population that’s selected, because people don’t die from malaria because of these high expressions of poor inflammatory cytokines but, they do then die from chronic diseases such as cancer because those same genes drive the cancers.
Now, the worldwide scientific organizations have shown a map of West Africa and Central Africa where malaria is very high. That same map shows that prostate cancer is more aggressive in that same area where malaria causes diseases. So the environment has a significant impact on the genome. The environment specifically impacts what I mentioned earlier, the oxidative stress, which is activated by reactive oxygen species. The reactive oxygen species is what is called an unpaired electron which makes it inactive and want…and therefore interacts with various environmental factors. These environmental factors also will activate through RNA methylation. Those two factors are the part of the genome that interacts with the environment, and those two factors interact with pro-inflammatory cytokines. So there is a triangle there that interacts or interplays during cancer and other diseases, and that’s where the environment impacts on the genome causing more cancers in particular populations.
Now, in terms of European Americans, there’s a difference between the Northern European genome gene pools and Southern European gene pools and prostate cancer. And Northern Europe prostate cancer is more aggressive compared to Southern Europe. So it’s not just among people of color. In fact, the color makes very little difference in whether you have an aggressive cancer, particularly in Sub-Saharan West Africa as well as in European. So I just wanted to make that point. And not many people are talking about this, because this is what is called population genetics. Epigenetic, transgenerational, hereditary genetics, those genes are transferred through populations over generations. So that’s what I’ve been learning more recently and there needs to be more discussion about population genetics. We know about familial hereditary, but this is different. This is population hereditary genetics.
Lisa Hatfield:
That is so interesting. So do you think over time there will be recommendations for…I think it depends too on funding for it, but for screening in certain areas of the world for prostate cancer or for any type of cancer where they have found this to be the case?
Dr. Isaac Powell:
Absolutely. That’s going to be a little while, but that I think should happen, yes.
Share Your Feedback
How Can Advanced Prostate Cancer Disparities Be Reduced?
/in PC Activated, PC Activated Expert Interviews, PC Videos WPS, PC Whole Patient Support, Prostate Cancer /by Kara RayburnHow Can Advanced Prostate Cancer Disparities Be Reduced? from Patient Empowerment Network on Vimeo.
What are some ways that advanced prostate cancer disparities can be reduced? Expert Dr. Isaac Powell from Karmanos Cancer Institute discusses early detection, recommended screening ages for African Americans versus European Americans, and how some government agencies can aid in reducing disparities.
See More from [ACT]IVATED Prostate Cancer
Related Resources:
Are There Worldwide Links to Aggressive Prostate Cancer?
Advanced Prostate Cancer Outcomes: Addressing Disparities and Exploring Solutions
Do Prostate Cancer Genetics Differ in African Americans?
Transcript:
Lisa Hatfield:
So, Dr. Powell, in your work, have you come across any innovative approaches or interventions that have shown promise in reducing racial disparities and improving outcomes for patients with advanced prostate cancer?
Dr. Isaac Powell:
Yes. Number one, educating the community about prostate cancer. Early detection is extremely important. I tell them that they should get their PSAs and digital rectal exams. I also tell them again, about obesity and exercise, how important it is to do that because it may prevent prostate cancer. And in terms of advanced disease, to just try to do the best they can and prolong in the survival by participating in clinical trials. And so I do quite a bit of educating in the African American community. In fact, in the ‘90s, we went to 51 churches, African American churches to talk about the prostate cancer and we also did testing. And what we learned in the ‘90s that mistrust factor was a major factor that prevented men from going in to be tested.
We also learned that men really don’t take care of their bodies as they should, and women have played a major role in the healthcare of men. So we start educating women about prostate cancer and encouraging their husbands to come in for examination, and very frequently, the wives have to bring their husbands in for testing or insist that they do that. I have this statement, I have a slide that says, men, they better care of their cars than they do of their bodies. And, in fact, they deny that they have any symptoms, and when they do, they don’t do anything about it until it’s too late.
Lisa Hatfield:
I have one follow-up question to that too, so you mentioned screenings, and I looked up prior to talking with you just to see what the general guidelines are for screenings for men, for prostate cancer, and it seems like they run the gamut. Do you have recommendations, or do you think the recommendations will change guidelines for screening and given your data and your research, is there a difference in screenings between European Americans versus African Americans?
Dr. Isaac Powell:
Yes. Because of what I’ve been talking about the cancer grows faster, and the significant cancers, the ones that are growing faster and become metastasized began in the 40s in African Americans, and so for European Americans has been recommended testing at age 50. I recommend age 40, American Cancer Society recommends age 45. Now, I believe at age 40, and I tell my patients that’s when they should start, African Americans that is, start testing for prostate cancer, specifically the PSA and digital rectal exam, and particularly if they have a family history. Now, the family history, if they only have one or two members is not much different than the aggressiveness among African Americans or European Americans.
If they have five or six members, not just a prostate cancer, but breast cancers as well, that means that they have a strong family history for having prostate cancer. If they have breast cancer, ovarian cancer in their family, or colon cancer, lung cancer, all those cancers are responsible for having a cancer and any specific cancer, if you have prostate cancer, breast cancer, you’re at risk for having colon cancer, for example. So that’s more recently talked about, multiple cancers in the family are even more important than having just prostate cancer in your family.
Lisa Hatfield:
Dr. Powell, given your expertise, what policy changes or healthcare system reforms do you believe are necessary to tackle the racial disparities in advanced prostate cancer care on a broader scale?
Dr. Isaac Powell:
Yes, policies are made by the government essentially. And so you have to encourage CDC, Centers Disease Control, US Preventive Services, which has done a disservice and prostate cancer. In fact, in 2012 they had that PSA did not show any evidence of preventing death from prostate cancer. They rescinded that 2017 recognizing that their recommendation 2012 was incorrect, and so US Preventive Services and the CDC, as well as the National Institute of Health NIH, have to come together and say, this disease is not only prostate but breast cancer, triple-negative breast cancer, colon cancer, lung cancer, all of these are more aggressive among African Americans, and we have to make a statement that screening has to be done earlier, education has to be emphasized.
And, in fact, COVID testing, it was almost mandatory on the circumstances that that happened. We used to demand that syphilis tests be tested if you got married. The government can also make it mandatory to be tested if your age, 45, American 50 for prostate cancer and maybe other cancers as well. So the government has to play a major role in establishing policies for testing, and I think that that would be very helpful in eliminating the disparity.
Lisa Hatifield:
And then from the patient perspective, it sounds like, and just trying to clarify this to when you talk about screenings for a patient to get screened to the appropriate time, that includes both the PSA test and the digital rectal exam, is that correct?
Dr. Isaac Powell:
Absolutely.
Share Your Feedback